ARCT is in the half way to its rapid gain pointNASDAQ:ARCT might rhyme its path in '19-'20 yrs
Now ARCT accumulating its power to the rapid jump in the middle of 2024.
Be aware, there was a drawdown in the end of '20's accumulation.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.21 USD
−29.73 M USD
157.75 M USD
24.76 M
About Arcturus Therapeutics Holdings Inc.
Sector
CEO
Joseph E. Payne
Headquarters
San Diego
Website
Founded
2013
FIGI
BBG00NNW8JK1
Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.
Arcturus testing ICE and 3 other lines from above - BULLISH
Here we see a test of an absorbtion. The test is were 4 lines come together. One of them is an ice line and the line were bearish absorption ttok place and was absorbed by bulls. This one is very very bullish. It can take time, but it will go up very fast. This is more likely. But be careful, if
Bought a small pilot position in ARCTNASDAQ:ARCT prices gapped up on strong volume (10x the average) during the previous earnings before moving up to the $28 resistance level. The $28 price level served as resistance previously back during feb and april of last year so it was not surprising to see prices encountered resistance at that
Long ARCTARCT has been holding steady at a solid support level and it’s primed and ready to make a run for it. There’s an inverse head and shoulders pattern that is showing flashes of a reversal. The green candle close above this channel is also confirming a breakout. Finally, we also have a strong bullish d
ARCT looks bullishGood company with new technology - Seems like we finally have hit the floor, now ready for a bullish move to the upside.
Short $ARCT Arcturus Therapeutics I will be shorting Arcturus Therapeutics to a range of $10-$12, and exit there.
$ARCT is a BUY nowArcturus Therapeutics Holdings Inc. $ARCT is set to be EBITDA positive in 2022 with a massive change in its revenue from 24.05M in 2021 to 326.44M in 2022. This is 12.57x increase in revenue. These numbers are estimates, but even with a large error margin we should see a drastic change in the price.
Potential Wyckoff Accumulation on $ARCTfinal charted thesis with considerable help from Wyckoff specialist @WyckoffOnCrypto
Possible Wyckoff Accumulation on $ARCTI have been trying to identify and study the Wyckoff patterns ever since the pattern became recognized in the recent bitcoin distribution and accumulation phases. i believe i see accumulation in $ARCT, which is a biotech with mRNA vaccines and treatments. The stock is lower float, heavily shorted, a
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ARCT is 19.63 USD — it has increased by 4.72% in the past 24 hours. Watch Arcturus Therapeutics Holdings Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Arcturus Therapeutics Holdings Inc. stocks are traded under the ticker ARCT.
ARCT stock has risen by 8.49% compared to the previous week, the month change is a −12.11% fall, over the last year Arcturus Therapeutics Holdings Inc. has showed a 0.08% increase.
We've gathered analysts' opinions on Arcturus Therapeutics Holdings Inc. future price: according to them, ARCT price has a max estimate of 140.00 USD and a min estimate of 25.00 USD. Watch ARCT chart and read a more detailed Arcturus Therapeutics Holdings Inc. stock forecast: see what analysts think of Arcturus Therapeutics Holdings Inc. and suggest that you do with its stocks.
ARCT reached its all-time high on Oct 4, 2013 with the price of 188.72 USD, and its all-time low was 4.11 USD and was reached on Dec 28, 2018. View more price dynamics on ARCT chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ARCT stock is 6.33% volatile and has beta coefficient of 2.75. Track Arcturus Therapeutics Holdings Inc. stock price on the chart and check out the list of the most volatile stocks — is Arcturus Therapeutics Holdings Inc. there?
Today Arcturus Therapeutics Holdings Inc. has the market capitalization of 531.59 M, it has decreased by −3.21% over the last week.
Yes, you can track Arcturus Therapeutics Holdings Inc. financials in yearly and quarterly reports right on TradingView.
Arcturus Therapeutics Holdings Inc. is going to release the next earnings report on Mar 3, 2025. Keep track of upcoming events with our Earnings Calendar.
ARCT earnings for the last quarter are −0.26 USD per share, whereas the estimation was −1.22 USD resulting in a 78.62% surprise. The estimated earnings for the next quarter are −0.68 USD per share. See more details about Arcturus Therapeutics Holdings Inc. earnings.
Arcturus Therapeutics Holdings Inc. revenue for the last quarter amounts to 41.67 M USD, despite the estimated figure of 36.59 M USD. In the next quarter, revenue is expected to reach 45.95 M USD.
ARCT net income for the last quarter is −6.90 M USD, while the quarter before that showed −17.22 M USD of net income which accounts for 59.90% change. Track more Arcturus Therapeutics Holdings Inc. financial stats to get the full picture.
No, ARCT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 180.00 employees. See our rating of the largest employees — is Arcturus Therapeutics Holdings Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Arcturus Therapeutics Holdings Inc. EBITDA is −26.93 M USD, and current EBITDA margin is −0.76%. See more stats in Arcturus Therapeutics Holdings Inc. financial statements.
Like other stocks, ARCT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Arcturus Therapeutics Holdings Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Arcturus Therapeutics Holdings Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Arcturus Therapeutics Holdings Inc. stock shows the sell signal. See more of Arcturus Therapeutics Holdings Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.